Pembrolizumab
2024000099
Phase 2 small_molecule active
Quick answer
Pembrolizumab for Triple Negative Breast Cancer is a Phase 2 program (small_molecule) at Inhibrx Biosciences with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Inhibrx Biosciences
- Indication
- Triple Negative Breast Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active